Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer.

Ercelep O, Alan O, Sahin D, Telli TA, Salva H, Tuylu TB, Babacan NA, Kaya S, Dane F, Ones T, Alkis H, Adli M, Yumuk F.

Clin Transl Oncol. 2018 Sep 18. doi: 10.1007/s12094-018-1949-6. [Epub ahead of print]

PMID:
30229391
2.

Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.

Lee VH, Chan WW, Lee EY, Choy TS, Ho PP, Leung DK, Lam KO, Kwong DL, Leung TW, Khong PL.

Am J Clin Oncol. 2016 Aug;39(4):355-62. doi: 10.1097/COC.0000000000000070.

PMID:
24710123
3.

Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.

Cacicedo J, Fernandez I, Del Hoyo O, Navarro A, Gomez-Iturriaga A, Pijoan JI, Martinez-Indart L, Escudero J, Gomez-Suarez J, de Zarate RO, Perez JF, Bilbao P, Rades D.

Clin Transl Oncol. 2017 Nov;19(11):1337-1349. doi: 10.1007/s12094-017-1674-6. Epub 2017 May 24.

PMID:
28540535
4.

Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer.

Atsumi K, Nakamura K, Abe K, Hirakawa M, Shioyama Y, Sasaki T, Baba S, Isoda T, Ohga S, Yoshitake T, Shinoto M, Asai K, Honda H.

J Radiat Res. 2013 Sep;54(5):890-8. doi: 10.1093/jrr/rrt021. Epub 2013 Mar 21.

5.

Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer.

Yap WK, Chang YC, Tseng CK, Hsieh CH, Chao YK, Su PJ, Hou MM, Yang CK, Pai PC, Lin CR, Hsieh CE, Wu YY, Hung TM.

Dis Esophagus. 2017 Aug 1;30(8):1-10. doi: 10.1093/dote/dox021.

PMID:
28575243
6.

Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.

Ohri N, Piperdi B, Garg MK, Bodner WR, Gucalp R, Perez-Soler R, Keller SM, Guha C.

Lung Cancer. 2015 Jan;87(1):23-7. doi: 10.1016/j.lungcan.2014.10.016. Epub 2014 Nov 6.

PMID:
25468149
7.

Can adaptive threshold-based metabolic tumor volume (MTV) and lean body mass corrected standard uptake value (SUL) predict prognosis in head and neck cancer patients treated with definitive radiotherapy/chemoradiotherapy?

Akagunduz OO, Savas R, Yalman D, Kocacelebi K, Esassolak M.

Nucl Med Biol. 2015 Nov;42(11):899-904. doi: 10.1016/j.nucmedbio.2015.06.007. Epub 2015 Jun 22.

PMID:
26275933
8.
9.

FDG PET using SUVmax for preoperative T-staging of esophageal squamous cell carcinoma with and without neoadjuvant chemoradiotherapy.

Huang YC, Lu HI, Huang SC, Hsu CC, Chiu NT, Wang YM, Chiu YC, Li SH.

BMC Med Imaging. 2017 Jan 5;17(1):1. doi: 10.1186/s12880-016-0171-7.

10.

Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience.

Oven Ustaalioglu BB, Gumus M, Bilici A, Seker M, Ustaalioglu R, Kefeli U, Salepci T, Canpolat N, Mayadagli A, Dogusoy I.

J BUON. 2010 Jul-Sep;15(3):529-36.

PMID:
20941823
11.

Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.

Ong LT, Dunphy M, Foster A, Woo KM, Zhang Z, Perez CA, Pietanza CM, Rosenzweig KE, Gelblum DY, Rimner A, Wu AJ.

Clin Lung Cancer. 2016 May;17(3):184-8. doi: 10.1016/j.cllc.2015.07.004. Epub 2015 Aug 3.

12.

Prognostic value of primary tumor SUVmax on pre-treatment 18F-FDG PET/CT imaging in patients with stage iii non-small cell lung cancer.

Yılmaz U, Batum Ö, Koparal H, Özbilek E, Kıraklı E.

Rev Esp Med Nucl Imagen Mol. 2018 Mar 17. pii: S2253-654X(17)30216-0. doi: 10.1016/j.remn.2017.11.006. [Epub ahead of print] English, Spanish.

PMID:
29559214
13.

Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer.

Kang SR, Song HC, Byun BH, Oh JR, Kim HS, Hong SP, Kwon SY, Chong A, Kim J, Cho SG, Park HJ, Kim YC, Ahn SJ, Min JJ, Bom HS.

Nucl Med Mol Imaging. 2014 Mar;48(1):16-25. doi: 10.1007/s13139-013-0231-7. Epub 2013 Sep 6.

14.

The increment in standardized uptake value determined using dual-phase 18F-FDG PET is a promising prognostic factor in non-small-cell lung cancer.

Chen HH, Lee BF, Su WC, Lai YH, Chen HY, Guo HR, Yao WJ, Chiu NT.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1478-85. doi: 10.1007/s00259-013-2452-5. Epub 2013 Jun 7.

PMID:
23744342
15.

Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.

Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Kim SK, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A.

J Clin Oncol. 2013 Oct 20;31(30):3823-30. doi: 10.1200/JCO.2012.47.5947. Epub 2013 Sep 16.

16.

Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.

Hyun SH, Ahn HK, Ahn MJ, Ahn YC, Kim J, Shim YM, Choi JY.

AJR Am J Roentgenol. 2015 Sep;205(3):623-8. doi: 10.2214/AJR.14.13847.

PMID:
26295651
17.

Is post-treatment standardized uptake value a prognostic factor in unresectable non-small cell lung carcinoma?

Yılmaz U, Yasar Z, Korkmaz E, Yalcın B, Koparal H, Ozbilek E.

Med Glas (Zenica). 2017 Aug 1;14(2):204-210. doi: 10.17392/898-17.

18.

Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer.

Dong X, Sun X, Sun L, Maxim PG, Xing L, Huang Y, Li W, Wan H, Zhao X, Xing L, Yu J.

PLoS One. 2016 Jun 20;11(6):e0157836. doi: 10.1371/journal.pone.0157836. eCollection 2016.

19.

Pretreatment F-18 FDG PET/CT Parameters to Evaluate Progression-Free Survival in Gastric Cancer.

Kim J, Lim ST, Na CJ, Han YH, Kim CY, Jeong HJ, Sohn MH.

Nucl Med Mol Imaging. 2014 Mar;48(1):33-40. doi: 10.1007/s13139-013-0243-3. Epub 2013 Nov 28.

20.

Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer.

Chen F, Yao Y, Ma C, Ma X, Wang Z, Lv T, Xiao X, Yin J, Song Y.

Transl Lung Cancer Res. 2015 Feb;4(1):18-26. doi: 10.3978/j.issn.2218-6751.2014.11.02.

Supplemental Content

Support Center